OR WAIT null SECS
July 23, 2024
Article
Despite recommendations, an analysis of more than 3.2 million youths suggests fewer than 15% of children/adolescents receive lipid screening.
July 10, 2024
Study finds women with familial hypercholesterolemia receive less intensive treatment and are less likely to achieve LDL-C goals than men.
July 09, 2024
First-time comprehensive evidence demonstrates the benefit of statins in reducing CVD risk for older adults with high cholesterol.
An analysis of CLEAR Outcomes and CTTC data suggest bempedoic acid holds its own relative to statin therapy for cardiovascular risk reduction normalized to 1 mmol/L reduction in LDL-C.
July 07, 2024
Our fourth and final quiz on the ESC/EAS 2019 guidelines on dyslipidemia spotlights lifestyle and nonpharmacological intervention recommendations.
July 02, 2024
Our Cardiology Month in Review for June 2024 spotlights the pharmacotherapies making waves within the pipeline, the latest news in dyslipidemia, and updates in heart failure.
June 28, 2024
Mirum Pharmaceuticals submitted an NDA for chenodiol tablets to treat CTX based on positive phase 3 RESTORE trial results.
June 27, 2024
Jennifer Goldman, RPh, PharmD, discusses how the pharmacologic advancements in recent years have shifted discussion around lipid, and cardiovascular risk, management in diabetes.
June 25, 2024
The FDA accepted the NDA for olezarsen, an RNA-targeted medicine, in familial chylomicronemia syndrome for priority review, with a PDUFA date set for December 19, 2024.
The latest in our series of quizzes on the ESC/EAS 2019 Dyslipidemia guidelines tests your knowledge on pharmacotherapy recommendations from the document!